SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Innodata, Inc. is a data engineering company, which engages in providing artificial intelligence software platforms and management of its services. It operates through the following business segments: Digital Data Solutions (DDS), Synodex, and Agility. The DDS segment combines deep neural networks and human expertise in multiple domains to make unstructured information useable. The Synodex segment enables clients in the insurance and healthcare sectors to transform medical records into useable digital data and to apply technologies to the digital data to augment decision support. The Agility segment provides tools and related professional services that enable public relations and communications professionals to discover influencers, amplify messages, monitor coverage, and measure the impact of campaigns. The company was founded by Todd H. Solomon in 1988 and is headquartered in Ridgefield Park, NJ.

Innodata Inc

Innodata Inc. is trending as investors eagerly await a "game-changer" partnership announcement, hinted at by management as coming prior to the new year. This potential alliance, especially in the federal and sovereign AI sectors, is fueling strong bullish sentiment for a significant revenue boost and short squeeze, though some in the community express skepticism over its timing and market impact.

Mannatech, Inc. engages in the development of nutritional supplements, topical and skin care products and weight-management products that target optimal health and wellness. Its product category includes integrative health, targeted health, wealth and fitness, skin care, essentials, and home. The company was founded by Marlin Ray Robbins and Samuel L. Caster in November 1993 and is headquartered in Flower Mound, TX.

Mannatech Inc

Mannatech (MTEX) is currently trending due to its exceptionally low public float, which is generating significant retail investor interest and speculation for a potential short squeeze. The community is actively discussing the stock's potential for rapid upward movement, with many eyeing key resistance levels and recent strong profitability metrics as drivers, despite some acknowledgment of past revenue trends. This micro-cap's tight share structure and increasing volume are fueling intense conversation around its parabolic breakout potential.

Ekso Bionics Holdings, Inc. engages in the provision of design, development, and sale of exoskeleton technology that currently has applications in healthcare and industrial markets. The company was founded on January 30, 2012 and is headquartered in San Rafael, CA.

Ekso Bionics Holdings Inc

Ekso Bionics is trending due to a proposed merger with Applied Digital's cloud computing business, aiming to pivot into an AI GPU compute platform named ChronoScale. This potential transformation from a medical device company to an AI infrastructure player is driving market conversation. The community is actively discussing the implications of this shift, with many anticipating a significant re-rating given exposure to AI and a low share float, though some express concerns regarding shareholder dilution.

Amgen, Inc. is a biotechnology company, which engages in the discovery, development, manufacture, and marketing of human therapeutics. The company was founded by William K. Bowes, Jr., Franklin Pitcher Johnson, Jr., George B. Rathmann, and Joseph Rubinfeld on April 8, 1980 and is headquartered in Thousand Oaks, CA.

AMGEN Inc.

Amgen is trending with significant pipeline news, including positive Phase 2 results for its obesity drug MariTide, which showed strong weight loss but also prompted community discussion around tolerability and potential dosing adjustments. Further boosting its portfolio, the company recently reported successful Phase 3 data for its Repatha cholesterol drug, alongside new FDA approvals for therapies in generalized myasthenia gravis and lung cancer, all while strategically engaging on U.S. drug pricing.

Roundhill ETF Trust - Roundhill GLP-1 & Weight Loss ETF

Roundhill GLP-1 & Weight Loss ETF

The Roundhill GLP-1 & Weight Loss ETF ($OZEM) is drawing significant attention as the therapeutic scope for GLP-1 drugs rapidly expands beyond obesity, with recent regulatory milestones for new indications fueling optimism. Investors are actively discussing the potential for increased insurance coverage and the long-term growth trajectory of this innovative sector, despite ongoing competitive dynamics.

Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.

Lilly(Eli) & Co

Eli Lilly is trending as its innovative pipeline continues to impress, with positive trial data for its next-generation obesity drug, retatrutide, and high anticipation for its oral GLP-1, orforglipron. The community is actively debating LLY's market leadership against fierce competition in the rapidly expanding weight-loss sector, with strong bullish sentiment contrasted by concerns over valuation and the competitive landscape. This ongoing innovation and strategic manufacturing expansion are cementing its role as a pharmaceutical giant.

Intelligent Living Application Group, Inc. engages in the manufacturing and selling of mechanical locksets. It focuses in producing mechanical locksets including locksets for outdoors such as main entrances and gates and indoors. The firm offers a range of original design manufacturer door locksets to various customer segments with classic to contemporary looks, functions and colors. The company was founded by Po Wang Hui in 1981 and is headquartered in Hong Kong.

Intelligent Living Application Group Inc

Intelligent Living Application Group is trending following strong revenue and gross profit growth reported in its latest financials, along with recent product launches in the smart lock market. Community discussion emphasizes the stock's potential for a significant upward move, drawing comparisons to other volatile Chinese and Hong Kong micro-cap names known for explosive price action and speculating on a potential short squeeze and active accumulation.

Avantis is the largest RWA perps DEX in DeFi, built on and backed by Base. Avantis allows users to trade crypto and real-world assets (RWAs), including FX, commodities, indices, and equities. Backed by Pantera and Coinbase, Avantis is the largest DEX on Base by volumes, and brings institutional-grade products to DeFi, letting users trade with up to 500x leverage in a transparent, permissionless environment.  Avantis is best known for launching zero-fee perpetuals (ZFP) — a first-of-its-kind primitive where traders only pay fees if they profit. They've also brought leveraged RWAs onchain. This has driven explosive growth: over $20B+ in cumulative volume and 15M+ run-rate revenues since Febrruary 2024.

Avantis

Avantis ($AVNT) is actively trending as a perpetual decentralized exchange (DEX) built on the Coinbase #base app, with the community highlighting its deep integration and competitive features like 500x leverage on various assets. Many believe it is significantly undervalued compared to rivals and anticipate substantial growth, fueled by planned buybacks and marketing efforts.

RAGE GUY (RAGE) is a cryptocurrency inspired by the Rage Guy meme, one of the earliest and most recognizable characters from internet rage comics. The project captures the cultural legacy of early meme history and brings it onto the blockchain in tokenized form. It is designed as a community-driven digital asset that celebrates internet culture, nostalgia, and the role memes play in shaping online communities.

Rage Guy

RAGE CRYPTO is trending fueled by its highly engaged community, passionately advocating for the "OG meme" narrative of Rage Comics and actively building out an ecosystem with tools like RageMaker and RageGames. This dedicated base expresses strong conviction, viewing RAGE as significantly undervalued and poised for substantial long-term growth as they lead a "return to the memes" within the broader market upswing.

Global X Funds - Global X Uranium ETF

Global X Uranium ETF

The Global X Uranium ETF is trending as the community increasingly links burgeoning AI energy demand to a critical need for stable nuclear power, solidifying uranium's strategic resource status. Investors are actively discussing the recent inclusion of uranium on the U.S. critical minerals list and a persistent supply deficit, further amplified by continuous buying from investment vehicles and supportive government policies. This confluence of factors underpins a strong long-term bullish outlook for the sector.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

$MRNA $pfe $jnj $bntx Does anyone know how the Eastern vaccines from Russia and China stand up to the Western vaccines? How come we never hear anything about their vaccines, maybe they are better? Maybe we should at least try them?

Mykah Hicks

erik

StockTwits Web

Moderna Inc

Johnson & Johnson

Pfizer Inc

BioNTech SE - ADR

 Does anyone know how the Eastern vaccines from Russia and China stand up to the Western vaccines? How come we never hear anything about their vaccines, maybe they are better? Maybe we should at least try them?

guilefort

@guile Here is a Chilenean study on the Sinovac vaccine: 65.9%  efficiency prior to Delta. Other studies have yielded 51%

https://www.nejm.org/doi/full/10.1056/NEJMoa2107715

Sputnik is technically similar to the JNJ vaccine, and should also have a similar efficacy (app. 80%). Problem there is a/o, that they tend to fail on their delivery contracts (e.g. Argentina, and a number of other Latin American countries).

Our apologies. An error occurred while setting your user cookie. Please set your browser to accept cookies to continue. NEJM.org uses cookies to improve performance by remembering your session ID when you navigate from page to page. This cookie stores just a session ID; no other information is captured.

Nejm

 Here is a Chilenean study on the Sinovac vaccine: 65.9%  efficiency prior to Delta. Other studies have yielded 51%





Sputnik is technically similar to the JNJ vaccine, and should also have a similar efficacy (app. 80%). Problem there is a/o, that they tend to fail on their delivery contracts (e.g. Argentina, and a number of other Latin American countries).

August Starke

@Augusto14 I wonder why American vaccines aren&#39;t marketed to South America

 I wonder why American vaccines aren't marketed to South America

@guile They are. See the extract from my Comirnaty ($BNTX / $PFE) 2021 order tally below. $MRNA also has a handful of deals in Latin America.

2022 boosters are a/o under negotiation with Costa Rica, Panama, Peru and Uruguay. PFE will do fill&amp;finish in Brazil from next year on.

💎💎💎💎 (Stock Gold Medalist🥇)

Bjorn Mjölgard

 They are. See the extract from my Comirnaty (

 also has a handful of deals in Latin America.

2022 boosters are a/o under negotiation with Costa Rica, Panama, Peru and Uruguay. PFE will do fill&finish in Brazil from next year on.